BioDelivery Sciences Intl licenses BEMA buprenorphine to Endo Pharma for mild to severe Chronic Pain

BioDelivery Sciences International (BDSI) has licensed the world rights of BEMA buprenorphine to Endo Pharmaceuticals. BEMA buprenorphine is a treatment for moderate to severe chronic pain which blends the opioid analgesic buprenorphine with the BioErodible MucoAdhesive (BEMA) drug delivery technology. A bioerodible polymer film about the size of a fingertip attaches to the inner lining of the cheek. The film then rapidly delivers its drug dose through the mucous membranes of the inner cheek, and completely dissolves in 15 to 30 minutes. The dug failed a Phase III trial recently but BDSI are proceeding with its development with a new nine month trial.